A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Eligible for screening study DCP 001
EA2183 is reopened to accrual with the implementation of Addendum 5 effective June 18, 2024.
